Dr Reddy’s Bitter Pill: Q4 Misses Street As Lenalidomide Fades And One Offs Bite

The Hyderabad based pharma major, known for its generic and specialty portfolio across the US, India and emerging markets, delivered a softer than expected quarter. Management has indicated that FY performance reflects the fading windfall from Lenalidomide, along with exceptional charges that weighed on reported profitability.

Quarterly Financial Snapshot

For Q4, total revenue from operations stood at Rs 75.46 billion, missing analyst expectations pegged at about Rs 82.46 billion. The moderation largely mirrors normalisation in key high margin products and a more competitive pricing environment in some regulated markets.

Profitability Under Pressure

Consolidated net profit came in at Rs 2.21 billion against street estimates of Rs 9.25 billion, highlighting the drag from lower Lenalidomide contribution and one off items. Adjusted for these factors, underlying business trends are likely to look more stable than headline profit suggests, but investors will watch margin trajectory closely.

Dividend And Outlook Commentary

Despite the earnings miss, the board has declared a dividend of Rs 8 per share, signalling confidence in the company’s balance sheet and longer term cash generation. Management commentary emphasises portfolio diversification beyond Lenalidomide, ramp up in new launches and productivity measures to support margins going ahead.

Key Results Highlights

• Q4 consolidated revenue from operations at Rs 75.46 billion versus IBES estimate of Rs 82.46 billion
• Q4 consolidated net profit at Rs 2.21 billion versus IBES estimate of Rs 9.25 billion
• Dividend of Rs 8 per equity share declared for the year
• Performance reflects lower Lenalidomide sales and multiple one off items
• Focus shifting to portfolio diversification, new launches and margin restoration

Sources: Money Control, Goodreturns, Angel One, Groww